Getinge AB (GNGBY) AI Stock Analysis

Getinge AB

(Other OTC:GNGBY)

Select Model

Rating:73Outperform

Price Target:$30.00▲(7.30% Upside)

Action:reiterated

Date:10/23/26

Positive earnings call and solid financial performance with improving profitability and cash flows are the primary drivers. Bullish technical trends provide additional support while valuation remains reasonable.

Positive Factors

Recurring and high-margin mixRecurring revenue at about two-thirds of sales provides a meaningful base of ongoing demand, while the 70% high-margin mix and stronger disposable exposure can support profitability. This should make earnings less dependent on individual capital-equipment projects over the next several quarters.

Negative Factors

Life Science weaknessContinued weakness in washer, isolator and sterilizer products is a durable drag on the Life Science segment, with positive bioprocessing and service performance not fully offsetting declines. Lower volumes also reduce operating leverage, limiting the segment’s contribution to group growth.

Getinge AB (GNGBY) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $7.62B
Dividend Yield: 1.89%
Average Volume (3M): 1,835
Price to Earnings (P/E): 26.3
Beta (1Y): 0.70
Revenue Growth: 4.09%
EPS Growth: 47.73%
Country: US
Employees: 12,118
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Devices

Getinge AB Business Overview & Revenue Model

Company Description

Getinge AB (publ) is a prominent global medical technology provider, delivering comprehensive products and solutions primarily to operating rooms, intensive care units, and sterilization departments. The company operates through three distinct segmen...

How the Company Makes Money

Getinge primarily makes money by selling medical technology equipment and systems, and by generating recurring revenue from services tied to its installed base. A significant portion of revenue comes from capital equipment sales to hospitals and heal...

Getinge AB Earnings Call Summary

Earnings Call Date:Oct 20, 2026(Q3-2026)|% Change Since:6.38%|Next Earnings Date:Jan 25, 2027

Earnings Call SentimentPositive

The call was predominantly positive. The company reported organic sales and order growth, improved margins, strong free cash flow, a solid balance sheet, record-high customer satisfaction, product-launch momentum and reiterated full-year guidance. These strengths were partly offset by continued Life Science weakness, elevated quality costs, balloon-pump capacity constraints, the surgical perfusion phaseout, regulatory timing and uncertainty around Q4 deliveries, tariffs and geopolitical conditions.

Positive Updates

Organic Sales and Order Intake Growth

Third-quarter net sales grew 2.1% organically, with positive development in most business areas, while order intake increased 2.6% organically.

Negative Updates

Life Science Decline in Washer, Isolator and Sterilizer Products

Life Science organic order intake declined slightly because positive performance in bioprocessing and service did not fully offset the continuing decline in the washer, isolator and sterilizer subsegment. Organic net sales also fell slightly, despite robust Sterile Transfer growth.

Company Guidance

Getinge reiterated its expectation for organic net sales growth to be in the range of 3% to 5% for 2026, adjusted for the phaseout of surgical perfusion, which is still expected to have net sales in 2026, declining from about SEK 250 million to SEK 50 million; year-to-date organic growth was 2.5%, and Q4 performance is expected to take the company into the span of 3% to 5%, although the lower part of the guidance span is easier and much more realistic than the upper part. The company’s adjusted EBITA margin was 15.6% on a rolling 12-month basis, 15.8% normalized excluding tariffs, and 14.5% excluding the tariff refund of SEK 381 million in Q2 and Q3 of 2026, versus an adjusted EBITA margin span of 16% to 19% by the end of 2028. Cost release is expected from the second half of this year, mainly impacting 2027 and 2028, while quality-related costs are expected to follow a gradual step down, with the decline definitely larger in '27 compared to '26, and then larger again in 2028; CardioSave’s approval time is still expected to be 6 to 9 months.

Getinge AB Financial Statement Overview

Summary

Strong TTM revenue growth of 63.5%, rising net profit margins to 8.2%, and robust operating and free cash flows offset by moderate leverage with debt-to-equity at 0.34.

Income Statement

76Positive

Balance Sheet

58Neutral

Cash Flow

71Positive

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	34.46B	34.97B	34.76B	31.83B	28.29B	27.05B
Gross Profit	16.49B	16.65B	16.15B	14.49B	13.41B	13.58B
EBITDA	6.81B	6.44B	5.31B	5.91B	5.70B	6.15B
Net Income	2.83B	2.26B	1.64B	2.41B	2.49B	2.97B
Balance Sheet
Total Assets	59.60B	56.51B	63.92B	53.52B	52.03B	44.55B
Cash, Cash Equivalents and Short-Term Investments	3.19B	3.40B	2.96B	2.73B	5.68B	4.08B
Total Debt	11.23B	10.88B	10.73B	8.08B	5.82B	4.31B
Total Liabilities	26.89B	27.01B	30.71B	23.18B	21.58B	19.38B
Stockholders Equity	32.65B	29.43B	33.01B	30.17B	30.04B	24.75B
Cash Flow
Free Cash Flow	4.32B	2.63B	3.27B	1.60B	2.23B	5.63B
Operating Cash Flow	5.51B	3.95B	4.58B	2.96B	3.37B	6.56B
Investing Cash Flow	-2.68B	-2.96B	-4.55B	-6.54B	-1.47B	-1.33B
Financing Cash Flow	-2.47B	-765.00M	504.00M	511.00M	-500.00M	-7.24B

Getinge AB Technical Analysis

Technical Analysis SentimentPositive

Last Price27.96

Price Trends

50DMA25.51Positive

100DMA24.19Positive

200DMA22.57Positive

Market Momentum

MACD0.75Negative

RSI74.83Negative

STOCH92.14Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GNGBY, the sentiment is Positive. The current price of 27.96 is above the 20-day moving average (MA) of 26.38, above the 50-day MA of 25.51, and above the 200-day MA of 22.57, indicating a bullish trend. The MACD of 0.75 indicates Negative momentum. The RSI at 74.83 is Negative, neither overbought nor oversold. The STOCH value of 92.14 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GNGBY.

Getinge AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

GNGBY against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MDT	74Outperform	$123.49B	24.28	10.60%	2.88%	9.77%	12.28%
GNGBY	73Outperform	$7.72B	26.30	9.13%	1.89%	4.09%	47.73%
GEHC	71Outperform	$34.62B	20.61	16.13%	0.18%	6.87%	-2.26%
ABT	69Neutral	$183.77B	40.80	9.12%	2.29%	10.00%	―
PHG	69Neutral	$26.35B	20.96	10.05%	3.59%	―	―
BSX	68Neutral	$60.84B	18.70	14.18%	―	8.88%	25.77%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

GNGBY and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
GNGBY	Getinge AB	27.90	5.03	21.99%
ABT	Abbott Laboratories	110.16	-12.59	-10.26%
BSX	Boston Scientific	44.32	-54.52	-55.16%
PHG	Koninklijke Philips N.V.	27.59	0.46	1.71%
MDT	Medtronic	99.29	11.77	13.45%
GEHC	Ge Healthcare Technologies Inc.	79.55	5.40	7.28%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 23, 2026

Getinge AB AI Stock Analysis